Search PubMed⌕ Search

Biomedical subjects

A Gola

Publications and source records attributed to A Gola.

At least 19 recordsLinked to original sources
PubMed1996

Comparison of Doppler echocardiography with thermodilution for assessing cardiac output in advanced congestive heart failure.

Noninvasive cardiac output estimation by Doppler echocardiography was compared with thermodilution and Fick oxygen methods in 73 patients with advanced chronic congestive heart failure due to dilated cardiomyopathy. In these patients, Doppler echocardiographic measurements showed a closer agreement with Fick measurements than that of thermodilution.

Cardiac Output↗
PubMed1996

[Pulmonary venous flow in patients with chronic heart failure: feasibility and additional value compared to transmitral flow for non-invasive estimation of pulmonary wedge pressure].

BACKGROUND: In many cardiac conditions, Doppler of transmitral flow has been showed to be related to left ventricular filling pressure, but several factors may limit its practical value in estimating pulmonary wedge pressure in patients with chronic heart failure. Pulmonary venous velocities directly depend on the oscillations of left atrial pressure. Recent studies suggest that transthoracic Doppler of pulmonary venous flow provides a more accurate estimation of pulmonary wedge pressure. However the relative values of transmitral and pulmonary venous flow for assessing pulmonary wedge pressure in patients with chronic heart failure have not been fully classified until now. Accordingly, we performed this study to assess the feasibility of transthoracic Doppler of pulmonary venous flow in patients with chronic heart failure and to evaluate whether it provides additional information regarding pulmonary wedge pressure when compared with Doppler indices of transmitral flow. METHODS: Simultaneous Doppler echocardiographic examinations and right heart catheterizations were performed prospectively in 300 consecutive patients with chronic heart failure due to dilated cardiomyopathy. The correlations of mitral and pulmonary venous flow velocity variables, left atrial volumes, mitral regurgitation jet area and left ventricular ejection fraction with pulmonary artery wedge pressure were evaluated. RESULTS: A complete recording of transthoracic pulmonary venous flow including all components was obtained in 66% of patients, while only systolic and diastolic forward flow were recorded in 88% of patients. Several indices, derived from pulmonary venous flow, were correlated with pulmonary wedge pressure; the strongest correlation was between systolic fraction of peak velocities and pulmonary wedge pressure (r = -0.76). This value was similar to that obtained between deceleration rate (r = 0.78) and deceleration time (r = -0.67) of transmitral flow and pulmonary wedge pressure. A systolic fraction > 40% showed a greater positive predictive value than restrictive pattern of transmitral flow for identifying patients with pulmonary wedge pressure > 18 mmHg (95% vs 86% p < 0.05). This accuracy is confirmed also in patients who had a single peak of transmitral flow. CONCLUSIONS: Doppler of pulmonary venous flow can be performed in a high percentage of patients with chronic heart failure due to dilated cardiomyopathy. The indices derived from transthoracic pulmonary venous flow are strongly correlated with pulmonary wedge pressure and improve the noninvasive identification of patients with high pulmonary wedge pressure, even when transmitral flow pattern is difficult to be interpreted.

Aged↗
PubMed1996

[Chronic granulocytic leukemia and an organ neoplasm in the same person].

Among 200 patients treated for chronic granulocytic leukaemia (CGL) 6 (3%) cases have been selected in whom a second synchronic or metachronic neoplasma coexisted. In one patient CGL was the first neoplasma and skin basalioma the second in line. In the remaining fife; Thyroid adenocarcinoma, adeno-carcinoma of the bowl (bis), epithelial carcinoma of the penis, epithelial carcinoma of the pulmonary, were followed respectively CGL as secondary tumor in same patient.

Adenocarcinoma↗
PubMed1994

[Interferon (IFN) in multiple myeloma and non-Hodgkin's lymphoma].

Interferon combined with cytostatics yielded in multiple myeloma more objective reactions than conventional chemotherapy. Survival time elongation was achieved solely by maintaining myeloma remissions with long term interferon administration. In non-Hodgkin's lymphoma combinations of cytostatics with interferon were more effective than conventional chemo-and radiotherapy only when used in low grade lymphomas of the nodular type. Evidence for longer survival of these patients still waits for presentation.

Humans↗
PubMed1993

Determinants of left ventricular function before and after regression of myocardial hypertrophy in hypertension.

Using digitized M-mode echocardiograms, we evaluated the determinants of left ventricular (LV) systolic and diastolic function in 30 hypertensives with LV hypertrophy (LV mass > 230 g and normal LV diastolic diameter), before (LV mass 319 +/- 26 g) and after normalization of LV mass (196 +/- 21 g) by antihypertensive treatment with angiotensin converting enzyme inhibitors. As a control group we selected 50 normal subjects. Using multiple regression analysis we studied the relative role of preload (LV end-diastolic diameter), afterload (end-systolic wall stress), inotropic state (systolic pressure/end-systolic LV diameter ratio), and LV mass on LV systolic (peak shortening rate of LV diameter) and diastolic function (peak lengthening rate of LV diameter). The major determinant of systolic function was the end-systolic stress in hypertensives before treatment and the systolic pressure/end-systolic LV diameter ratio in normals and in hypertensives after treatment. The major determinant of diastolic function was LV mass in hypertensives before treatment and end-systolic stress in normals and in hypertensives after normalization of LV mass by treatment. Preload seems not to influence LV function in normals and in hypertensives with normal LV diameter. The inotropic state is the major determinant of systolic function in normals and in hypertensives after treatment, whereas this role is played by afterload in hypertensives before treatment. The diastolic function is primarily influenced by after-load in normals and in hypertensives after regression of myocardial hypertrophy, whereas in hypertensives with myocardial hypertrophy LV mass is the major determinant of diastolic function.

Angiotensin-Converting Enzyme Inhibitors↗
PubMed1993

[Results of alternating treatment of multiple myeloma--cytostatics VBMCP and recombinant interferon alfa-2B].

In 19 patients with recently diagnosed multiple myeloma 3-week cycles of vincristine, BCNU, melphalan, cyclophosphamide and prednisone alternating with interferon were administered over 6-12 months. Results were compared with a control group of 33 myeloma patients treated exclusively with VBMCP cytostatics. In interferon treated patients objective response was more frequent (76%) and median survival time longer (above 35 months).

Adult↗
PubMed1992

[Advances in treatment of multiple myeloma].

Median survival time in multiple myeloma treated with melphalan and prednisone does not differ significantly from survivals yielded by combination of alkylating cytostatics. Intensive chemotherapy linked with marrow transplantation provides elongated complete remission more frequently in patients, who reached early remission by conventional means. Multidrug resistance of myeloma plasmocytes has been overcome by adding of verapamil to the VAD program. In recently diagnosed myelomas, it is more rational to assay the survival prognosis and access to intensive therapy.

Antineoplastic Combined Chemotherapy Protocols↗
PubMed1992

Myeloma cell resistance to melphalan, BCNU and epirubicin determined in vitro with the 3H-thymidine incorporation technique prior to chemotherapy.

Drug resistance of marrow plasma cells had been measured in vitro before chemotherapy was started. Resistance to melphalan was found in 20, to BCNU in 27 and to epirubicin in 38 out of 65 myelomas. Nineteen myelomas were resistant to a single cytostatic, 14 to two cytostatics and further 13 to all three. Patients with plasma cells resistant to melphalan in vitro failed to reduce 50% of monoclonal Ig plasma level after therapy along the VBMCP (M2) protocol, whereas sensitive myelomas responded to this program satisfactorily. Patients with cells resistant to two or three cytostatics, beside a bad therapeutic response, had also a shorter survival time. Results in vitro were in conformity with in vivo effects in 78%.

Adult↗
PubMed1991

[Analysis of the prognostic significance of serum immunoglobulins in Hodgkin's disease].

Main classes of serum immunoglobulins have been studied in plasma of patients with untreated Hodgkin's disease and correlations have been analyzed between their levels and the clinical stage of the disease, its histological type and the patient's age and survival. In the Hematology Department, Wrocław, in the years 1979-1989 to the study 115 cases were qualified, 59 were female, 56 male, 75 are still under treatment, whereas 40 died. Stage III B and IV B and histological type NS and MC prevailed. Mathematical analysis resulted in the following: In untreated Hodgkin's disease plasma levels of IgA, IgG, IgM were elevated compared to the controls. No correlation was found of the immunoglobulins elevations to the patients age, histological type, clinical stage and survival.

Adult↗
PubMed1990

In vitro determination of myeloma cell resistance to melphalan using the 3H-thymidine incorporation technique.

Plasma cells derived from marrow aspirates of 21 untreated myeloma patients have been cultured in RPMI 1640 medium containing 3H-thymidine and melphalan. Thereafter plasma cell-labelling index was determined autoradiographically. In 20 patients melphalan caused a measurable decrease in the percentage of labelled plasma cells. Decreases in labelling index ranging from -4% to 3% have been considered as indicating the resistance of myeloma cells to melphalan in vitro. Decreases within this range have been found in 7 patients. In other 13 myelomas with chemosensitive marrow plasma cells, melphalan did reduce the labelling index to values ranging from 4% to 24%. Some clinical implications of the tests are discussed.

Adult↗